Creo Medical Group Adjusts Valuation Metrics Amid Mixed Technical Trends

Creo Medical Group Plc, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the company's valuation metrics, moving from a classification of expensive to fair. The P/E ratio stands at 13, while the Price to Book Value is recorded at 0.97. Additionally, the company’s EV to EBIT and EV to EBITDA ratios are noted at -1.79 and -1.98, respectively, indicating a unique financial positioning within its industry. In terms of technical trends, there has been a transition from a bearish outlook to a mildly bearish stance. The MACD indicators show mixed signals across different time frames, with the weekly trend leaning mildly bearish and the monthly trend showing mild bullishness. The company's recent financial performance has been characterized by flat results for the quarter ending June 2025, alongside a reported annual decline in operating profit growth of -5.53% over the past five years. Overall, these adjustments highlight the evolving financial landscape for Creo Medical Group Plc, reflecting both its valuation and technical positioning in the market. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.